MVision AI obtains a new CE mark: Ultimate segmentation service now with lymph nodes

Less than a year after the CE marking of MVision Segmentation Service 1.1, our team has obtained another one: The state-of-the-art solution is now also available with lymph nodes. With the ability to contour lymph nodes, we enter an era where AI algorithms actually help clinicians in every contouring step of treatment planning.

Our algorithms accurately follow guidelines with lymph nodes making it efficient for clinicians to select the lymph levels to be treated and combine them in their treatment planning system. After reviewing, clinicians can simply apply a margin to create the planning target volume”, explains MVision AI CPO Jarkko Niemelä.

There are approximately 500-600 lymph nodes in a human body. Until now, clinicians have drawn lymph nodes with all lymph levels by hand. Going back and forth drawing and checking dozens of glands in one region, this method can take hours to complete. The risk for inter-observer variation is also high. 

MVision AI Segmentation Service 1.2 produces accurate auto-segmentation of lymph nodes for the pelvis, breast as well as head and neck in minutes. The system is trained to rigorously follow official guidelines. For the male pelvis, there are also two different versions available: pivotal and RTOG. A full list of guidelines in use can be found here. 

Lymph Nodes with Segmentation Service 1.2

The test use of the update has shown tremendous results. A recent study also supports its impact particularly in terms of decreased inter-observer variation with increased efficiency.

“The lymph node release indeed marks a new era, and I am extremely proud of our team for making it happen especially in the middle of the current circumstances“, concludes founder & CEO Mahmudul Hasan


Would you like to see the new update in action? Let us know and we’ll get back to you.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

26.8.2024

Lung Cancer Awareness–Examining Tobacco’s Effect

As August comes to a close, we take a moment to reflect on World Lung Cancer Day, observed earlier this month. This year’s focus has underscored the critical fact that tobacco smoking remains the leading cause of lung cancer. Understanding this connection is essential for both prevention and treatment, emphasizing…

News

6.8.2024

MVision AI Secures CDSCO Approval to Revolutionize Cancer Treatment Planning in India

HELSINKI, Finland – August, 2024 MVision AI is excited to announce that our application for MVision AI Segmentation (Contour+) has been approved by the Central Drugs Standard Control Organization (CDSCO) under the “Image Segmentation Application Software” category. This approval facilitates the deployment of our advanced image analysis algorithms in radiation…

Press Releases

2.7.2024

Breaking New Ground: MVision AI Contour+ for Upright MRI Scans

Results on testing MVision AI Contour+ for an ingenious and modern approach in radiation therapy have been recently presented at the 62nd Particle Therapy Co-Operative Group (PTCOG) conference in Singapore. Despite being trained using supine MR data and a different magnetic strength from different scanners, authors reported that MVision AI's…

Articles